07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

Atu027: Phase Ib/IIa final data

Final data from the Phase IIa portion of the open-label, German Phase Ib/IIa Atu027-I-02 trial in 23 patients with locally advanced or metastatic pancreatic adenocarcinoma showed that twice-weekly Atu027 for 4 weeks plus once-weekly gemcitabine...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Atu027: Additional Phase IIa data

A post hoc analysis of the subgroup of 19 patients with metastatic pancreatic adenocarcinoma in the Phase IIa portion of the open-label, German Phase Ib/IIa Atu027-I-02 trial showed that twice-weekly Atu027 for 4 weeks plus...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Atu027: Preliminary Phase IIa data

Preliminary data from the Phase IIa portion of the open-label, German Phase Ib/IIa Atu027-I-02 trial in 23 patients with locally advanced or metastatic pancreatic adenocarcinoma showed that twice-weekly Atu027 for 4 weeks plus once-weekly gemcitabine...
01:54 , Mar 24, 2015 |  BC Extra  |  Clinical News

Silence golden on pancreatic cancer data

Silence Therapeutics plc (LSE:SLN) climbed 50.5p (21%) to 288p after preliminary Phase IIa data suggested the biotech's Atu027 had a dose-dependent effect in advanced pancreatic cancer patients. The study included 23 patients receiving one of...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Atu027: Completed Phase Ib/IIa enrollment

Silence said it completed enrollment of 24 patients with locally advanced or metastatic pancreatic adenocarcinoma in the Phase IIa portion of an open-label, German Phase Ib/IIa trial of Atu027 plus gemcitabine in 4-week cycles. The...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

Atu027: Phase Ib/IIa ongoing

Silence said a DSMB recommended continuation into the main portion of an open-label, German Phase Ib/IIa trial evaluating Atu027 plus gemcitabine in 4-week cycles in about 30 patients. The decision was based on safety data...
23:54 , Apr 12, 2013 |  BC Extra  |  Financial News

Silence proposes L19M placing

Silence Therapeutics plc (LSE:SLN) proposed to raise up to L19 million ($29.2 million) through the sale of up to 9.5 million shares at 200p in a placing. All figures reflect a 1-for-50 reverse stock split,...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

Alnylam, Silence Therapeutics, BASF, Sanofi, Max Planck Society, MIT, University of Massachusetts, Whitehead Institute chemistry news

Alnylam said the Opposition Division of the European Patent Office (EPO) upheld the company's Tuschl I patent, European Patent No. 1309726. The patent includes 14 claims broadly covering the use of double-stranded RNAs (dsRNAs) for...
08:00 , Dec 12, 2011 |  BC Week In Review  |  Company News

Alnylam, Silence Therapeutics cancer news

Silence said the Opposition Division of the European Patent Office upheld an amended form of European Patent EP 1536827, which covers the use of protein kinase N (PKN) beta as a downstream target of the...